Uncertainty has become the operating condition, not the exception.

In May 2026, senior external manufacturing executives from major pharmaceutical companies gathered before CDMO Live Europe to work through two questions that have moved firmly to the top of the external manufacturing agenda in 2026:

• How do you build genuine supply resilience when dual sourcing is commercially impossible for most of your portfolio — and the geopolitical environment keeps shifting beneath you?
• What does the much-discussed “strategic” CDMO partnership really look like — and what separates it from a transactional relationship with a better contract?

Download this report to access our takeaways from the think tank, in partnership with WuXi STA.

The report is published under ‘Chatham House Rules’ with all quotes unattributed.

Complete the form to download your complimentary copy